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Abstract: Aims of the study were to evaluate the expression Cytokeratin 5/6(CK5/6) and Epidermal Growth Factor Receptor (EGFR) 
among triple negative breast cancers and high grade infiltrating duct carcinomas. Further to probe if triple negative phenotype can be a 
surrogate marker for basal phenotype and to correlate the expression of basal markers with disease free survivals among triple negative 
phenotype and high grade infiltrating duct carcinomas.
Methods: Expression of CK5/6 and EGFR were studied by Immunohistochemistry (IHC) in 31 triple negative and 19 non-triple 
  negative high grade breast carcinomas.
Results: 21 of the 31 triple negative phenotype (67.7%) breast carcinomas and 7 out of 19 non-triple negative (36.8%) breast carcinomas 
showed expression of basal markers (CK5/6 and/or over-expression of EGFR). There were statistically significant associations of all 
the basal-like tumors with negative hormonal status. The basal markers positive phenotype subjects had a shorter disease free interval 
as compared to basal markers negative phenotype subjects.
Conclusion: Basal-like breast carcinomas constitute a unique clinical and pathological entity, characterized by high tumor grade and a 
propensity for lack of ER, PR and HER2 expression. Basal phenotypes have a more aggressive course than non-basal phenotype. “Triple 
negative” status cannot be used as a surrogate for “basal marker expression”.
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Introduction
Breast cancer is a multifaceted disease comprising of 
distinct biological subtypes with diverse natural his-
tory, presenting a varied spectrum of clinical, patho-
logic and molecular features with different prognostic 
and  therapeutic  implications.1  Recent  attention  has 
been directed singularly at molecular classifications 
of breast cancer.1,2
Currently, routine clinical management of breast 
cancer  incorporates  specific  molecular  markers; 
namely ER-estrogen receptor, PR-progesterone recep-
tor, HER2-human epidermal growth factor receptor 
2 gene, that have been proven to provide therapeutic, 
predictive and prognostic value.3
Global  gene  expression  profiles  (GEP)  has  led 
to the identification of five molecular breast cancer 
subtypes  (Table  1),  of  which  only  four  have  been 
well defined while the fifth being “normal mammary 
stromal cells like” is poorly defined.
The  hormonal  positive  group  (ER  and/or  PR 
  positive) of tumors are clustered into a large group 
named ‘  luminal class’ which is further sub-divided 
into Luminal A and Luminal B depending on presence 
or absence of HER2 positivity. The hormonal negative 
group of tumors is comprised of
1. HER-2+ type: Tumors with gene characteristics of 
HER2 amplification
2. Basal type: Tumors with gene expression that is 
similar to normal basal/myoepithelial cells
3. Normal  breast  stromal  cells  like  tumors  that 
lack  hormonal  group,  HER2  amplification  and 
basal-like expression profile which are similar to 
normal mammary stromal cells.3,4
Breast  cancers  ER/PR−,  HER2−  phenotype  are 
  classified  as  triple  negative/basal-like  tumors3  and 
have poor prognosis and therapy response.5
Although  an  ER  negative/PR  negative/HER-2 
negative  (ER-/PR-/HER-2-)  or  “triple  negative” 
immunophenotype is considered sufficient to identify 
basal-like  tumors,  increasing  evidence  shows  that 
“basal-like” and “triple negative” are not   synonymous. 
A more complete definition should include expres-
sion  of  basal  cytokeratins  (CK5/6,  14,  17)  and/or 
over-  expression of human epidermal growth factor 
receptor  1  (HER-1).6  This  is  further  supported  by 
recent evidence suggesting that triple negative breast 
carcinomas  represent  a  more  heterogeneous  group 
than  basal-like  tumors.7  The  aggressive  behavior 
of these triple negative breast tumors is due to the 
  co-expression of basal markers.8
Basal cytokeratins (CK) represent a large number 
of high molecular weight (HMW) cytokeratins mainly 
seen in the basal cell layers of stratified   epithelium.9 
In  the  human  breast,  these  cytokeratins  are  also 
expressed in the basally-located myo-  epithelial cell 
layer and in a small proportion of luminal epithelial 
cells  of  the  glands.10  Breast  tumors    characterized 
by CK5, CK14 and CK17 expression are classified 
as basal phenotype. As these markers were seen in 
the  basal  layers,  “basalness”  was  often  interpreted 
as a sign of a myo-epithelial origin which created 
  confusion.  However  it  has  been  observed  that  not 
only grade 3 invasive ductal carcinomas (NOS), but 
also other histological breast cancer subgroups, such 
as  metaplastic  and  medullary  carcinomas,  with  or 
without associated BRCA1 mutations also expressed 
CK5/6, a basal marker.11 In contrast to all other breast 
cancer  subgroups,  metaplastic  subgroups  harbor 
EGFR-amplifications,11 more commonly than other 
types  of  breast  cancer.12  Thus,  breast  carcinomas 
have been deemed basal when they express HMW-
cytokeratin even in a single malignant cell.12 “Basal 
phenotypes” of breast carcinomas are   usually ER, PR 
Table 1. Types of invasive breast carcinomas based on gene expression profiling (GEP).
Hormonal class Molecular sub-type eR and pR  
expression
HeR2-neu  
expression
Basal markers  
expression
hormone positive  
“luminal class”
Luminal A eR/PR +ve heR-2 negative
Luminal B eR/PR +ve heR-2 positive
hormone negative  
“nonluminal class”
heR-2 eR/PR −ve heR-2 positive
Triple negative eR/PR −ve heR-2 negative Basal markers +ve
normal breast stromal cells like eR/PR −ve heR-2 negative Basal markers −veClinico-pathological characteristics of high grade breast carcinomas
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and HER-2 neu negative and have been consistently 
associated  with  expression  of  epidermal  growth 
factor receptor (EGFR), c-kit, p53, and p63.13 Basal 
breast cancer requires a set of diagnostic markers, 
and has been defined differently in different studies.12 
In 2009, Rakha and Ellis,3,14 recommended 4 basal 
markers, namely C5/6, CK14, CK17 and EGFR of 
which at-least 2 should be positive to be termed as 
Basal-like breast cancer.
The present study has been undertaken to:
1. Evaluate  the  expression  of  two  basal    markers 
(CK5/6  and  EGFR)  among  triple  negative 
breast  cancers  and  high  grade  infiltrating  duct 
carcinomas.
2. Study whether triple negative phenotype (IHC pro-
file) can be a surrogate marker (profile) for basal 
phenotype.
3. Correlate the expression of basal markers with dis-
ease free survivals among triple negative pheno-
type and high grade infiltrating duct carcinomas.
Materials and Methods
A total of 50 cases of either triple negative or high grade 
(primary  and  recurrent)  invasive  breast  carcinoma 
were retrieved from the files of Pathology Department, 
Kasturba  Medical  College  Hospital,  Manipal 
University, Manipal, India. Patients were diagnosed 
and treated in our institution between January 1, 2006 
and December 31, 2007. Information regarding age, 
menopausal  status,  cancer  characteristics,  stage  of 
cancer at diagnosis, nodal disease status, periductal 
elastosis, specifics of treatment, recurrence, date and 
location of recurrence, date and cause of death, and 
length of survival were obtained from case records. The 
medical records of the subjects included in the study 
were followed up until August 1, 2009. This study was 
approved by the Institutional Ethics Committee.
Resources
Pathological diagnosis
All  surgical  tissue  specimens  were  fixed  in  10% 
formaldehyde, embedded in paraffin, sectioned and 
stained  with  Hematoxylin/Eosin.  The  tumors  were 
classified  and  graded  according  to  World  Health 
Organization  classification  and  the  Nottingham 
modification of the (Scarff-Bloom-Richardson) SBR 
system, respectively.
immuno-histochemical staining
Four  micrometer  sections  attached  on  poly-lysine 
coated slides and incubated overnight at 37 °C. The 
slides were dewaxed in xylene, rehydrated in graded 
ethanol, distilled water and covered with 10 mM citrate 
buffer (pH 6). They were then incubated for 30   minutes 
with  primary  monoclonal  anti-  bodies  against  HER2 
(DAKO,  clone  250,  1:100,  antigen  retrieval:  2  min 
pressure cooker), ER (DAKO, clone SP1, 1:50, antigen 
retrieval: 2 minutes   pressure cooker) and PR (DAKO, 
clone PgR636, 1:50, antigen retrieval: 2 minutes pressure 
cooker), CK5/CK6 (DAKO, clone D5/16B4,1:50, anti-
gen retrieval: 18 min microwave oven), EGFR(DAKO 
clone  2-18c9,  1:40,  antigen  retrieval:  proteinase  K) 
followed by incubation with biotin-labeled secondary 
antibodies. The streptavidin-peroxidase complex was 
visualized using di-aminobenzidine as a chromogenic 
substrate. For each run of staining, a positive control 
slide was prepared from breast carcinoma known to be 
positive for the proteins studied.
eR/pR
The sections were assessed for ER and PR by Quick 
score. For the current study 1% of the cells showing 
ER positivity were considered as positive.
heR2-neu
The  sections  were  assessed  for  HER2  membrane 
staining according to American Society of Clinical 
  Oncology/College of American Pathologists guideline 
recommendations for human epidermal growth factor 
receptor 2 testing in breast cancer.
For the current study, complete, dark membrane 
staining in .30% of the cells was scored as 3+ and 
was taken as positive. Less than 30% of the cells with 
complete  dark  membrane  positivity/or  incomplete 
light membrane staining was scored as 2+ and was 
considered negative. However they were advised to 
look for over-amplification of HER2 neu by fluores-
cent in-situ hybridization (FISH).
case selection
Based on the immunohistochemical staining   status (ER, 
PR and HER2), we included 31   triple   negative pheno-
type [ER/PR-, HER2-] breast   carcinomas and 19 non-
triple negative high grade breast carcinomas (4 Luminal 
B phenotype [ER/PR+, HER2+]; 13 Luminal A pheno-Choccalingam et al
24  Breast Cancer: Basic and Clinical Research 2012:6
type [ER/PR+, HER2−]; 2 HER2 positive phenotype 
[ER/PR−, HER2+]). Subsequently all the triple negative 
breast carcinomas and high grade (primary and recur-
rent) breast carcinomas were assessed for expression 
of CK5/6 and EGFR.
eGFR
Only  membrane  staining  was  assessed  for  EGFR 
according to DAKO criteria (Table 2).
For the current study, EGFR over-expression of 
any intensity in more than 1% of cells was considered 
as positive basal marker. Examples of different stain-
ing results are shown in Figure 1A and B.
cK5/6
Any  cytoplasmic  expression  in  definite  neoplas-
tic cells or tissue was considered as positive result. 
Examples of different staining results are shown in 
Figure 1C and D.
Pathology  slides  were  reviewed  concurrently 
by two pathologists for grading and evaluating the 
immunohistochemical stains.
statistical Analysis
The SPSS version 16.0 statistical program was used for 
analysis. Patient characteristics were compared using 
Fisher’s exact test. Two tailed P values #0.05 were 
considered  significant.  Borderline  statistical  signifi-
cance was defined as P values between 0.05 and 0.10. 
Disease free interval was calculated from the date of 
starting treatment until the recurrence of breast cancer. 
Survival  plots  and  cumulative  survival  probabilities 
were estimated using the Kaplan-Meier method.
Results
Twelve out of the thirty one triple negative (basal-like) 
phenotype  [38.7%]  breast  carcinomas  showed 
CK5/6 expression. Expression of CK5/6 was found 
only in one non triple negative tumor (Luminal A 
phenotype).
EGFR  over-expression  was  found  in  eighteen 
out of thirty one triple negative (basal-like) pheno-
type [58.1%] breast carcinomas. Over-expression of 
EGFR was also found in non triple negative tumors 
namely 25% of Luminal B phenotype [1 out of 4], 
23.1% of Luminal A phenotype [3 out of 13] and 
100% of HER2 phenotype [2 out of 2] tumors.
Taken together, twenty one out of the thirty one 
triple negative (basal-like) phenotype [67.7%] breast 
carcinomas showed expression of CK5/6 and/or over-
expression of EGFR. (Table 3)
There were statistically significant associations of 
all the basal-like tumors (CK5/6, EGFR, CK5/6 and/
or EGFR) with negative hormonal status, and nega-
tive estrogen receptor expression. Negative proges-
terone receptor status was strongly associated only 
with CK5/6 and basal marker (CK5/6 and/or EGFR) 
expression. (Table 4)
There was a significant association between neg-
ative  peri-ductal  elastosis  and  over-expression  of 
EGFR. There was a borderline association between 
EGFR over-expression and breast carcinomas which 
showed metaplasia less than 20% of tumor area and 
all the metaplastic breast tumors. (Table 5)
Basal Marker expression  
and patient survival
Kaplan  Meier  plots  with  reference  to  disease  free 
survivals were similar for triple negative breast can-
cers expressing EGFR and breast cancers expressing 
EGFR and/or CK5/6 basal markers (Figure 2A and C). 
Though not statistically significant, the basal mark-
ers positive phenotype subjects had a shorter disease 
free interval as compared to basal marker negative 
  phenotype.  Despite  the  fact  that  basal  phenotype 
had shorter disease free interval in the initial follow 
up period, relatively better disease free interval was 
noted in the later follow up period, which is similar to 
the observations made by Arnes et al.15
Disease free survivals for triple negatives express-
ing C5/6 was different (Figure 1B) from the other two 
basal marker phenotype. They showed longer disease 
free interval in the initial period and became shorter 
in the later part of the follow up.
Table 2. egFR assessment.
score to 
report
eGFR 
assessment
staining pattern
1+ Weak Faint and incomplete  
membrane positivity
2+ Moderate Moderate and complete/
incomplete membrane positivity
3+ Strong Strong and complete  
membrane positivityClinico-pathological characteristics of high grade breast carcinomas
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Discussion
We  examined  expression  of  EGFR  and  CK5/6  by 
immunohistochemistry in all the triple negative and 
high grade breast carcinomas. In the majority of the 
triple  negative  breast  tumors  (21/31,  67.7%),  we 
found expression of at least one of the markers EGFR 
and/or CK5/6. The individual basal markers namely 
CK5/6 was expressed in more than a quarter of triple 
negative tumors (12/31, 38.7%) and EGFR was over-
expressed in more than half of the triple   negative breast 
tumors (18/31, 58.1%). Our observations imply a large 
overlap between “triple   negativity” and “basalness”. 
Similar opinions were expressed by Rakha et al.3 Our 
data also shows that EGFR and CK5/6 are also expressed 
in other immunohistochemical subtypes of breast can-
cer. Further, CK5/6 was found only in one non triple 
negative tumor namely   Luminal A phenotype breast 
cancer whereas EGFR was over-expressed in all the 
HER2 phenotype breast tumors (100%). Recently the 
“so called basoluminal phenotype” has been described 
and is characterized by expression of basal markers and 
HER-2 expression in the luminal cells.16 In the pres-
ent study 2 cases of basoluminal phenotype have been 
documented. Over-expression of EGFR was also seen 
in a quarter of Luminal B phenotype breast tumors (1/4, 
25%) and a little less than a quarter of luminal A phe-
notype breast tumors (3/13, 23.1%). Though our study 
population was small, these   observations suggest that 
Table 3. Summary of CK5/6 and egFR expression data by immunohistochemistry.
Tumour phenotype Basal markers cK5/6 eGFR
Luminal B 1/4 (25.0) 0/4 1/4 (25.0)
Luminal A 4/13 (30.8) 1/13 (7.7) 3/13 (23.1)
heR2 2/2 (100) 0/2 2/2 (100)
Triple negative (basal like) 21/31 (67.7) 12/31 (38.7) 18/31 (58.1)
All 28/50 (56.0) 13/50 (26.0) 24/50 (48.0)
note: Percentages are given in parentheses. 
Abbreviations: CK, cytokeratin; egFR, epidermal growth factor receptor.
A B
CD
Figure 1. (A) egFR negative staining; (B) egFR positive staining; (c) CK5/6 negative staining; (D) CK5/6 positive staining.Choccalingam et al
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Table 4. Associations between CK5/6, egFR and basal markers (CK5/6 and/or egFR) and hormonal status.
prognostic factors cK5/6 eGFR Basal markers
eR + - P value + - P value + - P value
Positive 1 16 0.020 4 13 0.013 5 12 0.007
negative 12 21 20 13 23 10
pR
Positive 0 13 0.013 4 9 nS 4 9 0.033
negative 13 24 20 17 24 13
HeR2
Positive 0 6 nS 3 3 nS 3 3 nS
negative 13 31 21 23 25 19
Hormonal status
Positive 1 16 0.020 4 13 0.013 5 12 0.007
negative 12 21 20 13 23 10
Triple negative phenotype
non-triple negative 1 18 0.009 6 13 0.069 7 12 0.033
Triple negative 12 19 18 13 21 10
Abbreviations: CK, cytokeratin; EGFR, epidermal growth factor receptor; ER, estrogen receptor; PR, progesterone receptor; NS, not significant.
expression of CK5/6 and especially EGFR are not only 
limited to triple negative phenotype of breast cancers 
but are also expressed in 22.6% of non-triple negative 
phenotype of breast cancers (7/19 ie, 25% of luminal 
B, 30.8% of luminal A, 100% of HER2). In view of the 
highly complex pathogenesis of breast cancer and pres-
ence of basal markers among triple negative and non 
triple negative breast cancers, it would be imprudent 
to equate triple negative phenotype to basal-like breast 
cancers. Larger studies are needed to explore these 
observations in detail and to study overlap between the 
different basal markers in different immune-phenotypic 
subtypes of breast cancer.
In fact, triple negative phenotypic breast cancers 
are a clinically and molecularly heterogeneous dis-
ease  that  encompasses  more  than  one  entity.  In 
addition to basal-like breast tumors, triple negative 
phenotype tumors also include ‘normal breast-like’ 
cancers  (32.3%  of  the  triple  negative  phenotype). 
Similar to our study, a separate basal marker negative, 
triple negative breast cancer subtype was reported in 
  various studies and was found to have a prognosis 
which seems to better than basal-like breast cancer.3
Either EGFR over-expression or CK5/6 expression 
has been included in the definition of a “core basal pro-
file”.15 In the present study, the basal marker expres-
sion was compared with different prognostic factors. 
Similar to our observations, there was a borderline 
association between EGFR over-expression and breast 
carcinomas which showed metaplastic changes and 
metaplastic breast carcinomas.11 Breast tumors with 
metaplastic changes seemed to over express EGFR, 
however a larger sample size would have produced a 
significant P value. A breast tumor was categorized as 
metaplastic breast carcinoma if metaplastic changes 
occupied more than 20% of the tumor area11 and cate-
gorized as breast carcinoma with metaplastic changes if 
the metaplastic changes occupied less than 20% of the 
tumor area. Besides classical sarcomatoid metaplasia, 
other metaplasias like apocrine, squamous and chon-
droid were also classified as metaplastic changes in 
the present study. In concordance with other studies4 
all the basal markers showed a significant association 
with negative   estrogen receptor expression and hor-
monal negative sub-group of breast cancers.
In the present study there was no significant asso-
ciation  between  basal  phenotype  and  lymph  node 
status, histologic grade, menopausal status, age group 
and HER2 status. However, our limited study popula-
tion must be kept in mind before drawing any further 
conclusion. In the present study, periductal-elastosis 
was found to be a good predictor of EGFR expres-
sion, unlike the conclusion drawn by Remmele et al17 
in their study.
The  disease-free  interval  of  basal  marker  positive 
carcinoma was shorter than that of patients with basal 
markers  negative  tumors.  Similar  observations  were 
made  in  other  studies.3,18  However,  CK5/6  positive Clinico-pathological characteristics of high grade breast carcinomas
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Table 5. Associations between CK5/6, egFR and basal markers (CK5/6 and/or egFR) and prognostic factors.
prognostic factors cK5/6 eGFR Basal markers
+ - P value + - P value + - P value
Age
$50 years 5 17 nS 11 11 nS 13 9 nS
,50 years 8 20 13 15 15 13
Menopausal status
Peri-menopausal 8 17 nS 12 13 nS 14 11 nS
Post-menopausal 5 20 12 13 14 11
Histologic type
iDC-nos 12 36 nS 23 25 nS 26 22 nS
iDC-special type 1 1 1 1 2 0
Histologic grade
grade 1 and 2 2 4 nS 4 2 nS 5 1 nS
grade 3 21 23 20 24 23 21
periductal elastosis
Present 0 7 nS 1 6 0.037 1 6 0.014
negative 12 21 20 13 23 10
Lymph node status
Positive 6 23 nS 14 15 nS 16 13 nS
negative 7 14 10 11 12 9
number of positive lymph nodes
1–4 4 14 nS 8 10 nS 10 8 nS
$5 2 9 6 5 6 5
Metaplasia
Present 1 7 nS 6 2 0.095 6 2 nS
Absent 12 30 18 24 22 20
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Figure 2. Basal marker expression and disease survival. (A) Basal markers {egFR and/or CK5/6} expression and disease free survival; (B) CK5/6 
  expression and disease free survival; (c) egFR expression and disease free survival.Choccalingam et al
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phenotype subjects had a better prognosis compared to 
basal marker (CK5/6 and/or EGFR) positive phenotype 
subjects. The number of cases in each sub-group restricts 
us from drawing definite conclusions. The poor prognosis 
of basal-like breast carcinomas is noted in the initial days 
of follow up and then the difference in outcome between 
basal and non-basal tumors became less evident.
conclusion
Basal-like breast carcinomas constitute a unique clinical 
and pathological entity, characterized by high tumor grade 
and a propensity for lack of ER, PR and HER2 expression. 
However, basal-like carcinomas are not synonymous with 
triple negative carcinomas. Metaplastic carcinomas are 
more likely to show basal phenotype. Basal phenotypes 
have a more aggressive course than non-basal phenotype, 
as shown by the shorter disease free intervals.
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